Form 4: ACHIEVE LIFE SCIENCES CLO Granted 250,000 Stock Options

Achieve Life Sciences' Chief Legal Officer, Erik Atkisson, was granted 250,000 stock options with an exercise price of $4.78, vesting over four years.

Summary

• Erik Atkisson, Chief Legal Officer of ACHIEVE LIFE SCIENCES, INC. (ACHV), acquired 250,000 stock options.
• The transaction date for the option grant was December 4, 2025.
• The exercise price for these stock options is $4.78 per share.
• The options will vest as to 1/4 of the total award on the first anniversary of October 20, 2025, and then in substantially equal monthly installments over the subsequent 36 months.
• The vesting is contingent upon Mr. Atkisson's continued provision of service to the Issuer on each vesting date.
• The stock options have an expiration date of December 4, 2035.
• Following this transaction, Mr. Atkisson beneficially owns 250,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard compensation event that aligns management's interests with shareholder value creation, generally viewed as a neutral to slightly positive development for corporate governance and long-term strategy.

Positives

• The grant of stock options to the Chief Legal Officer aligns management's long-term interests with those of shareholders, incentivizing value creation.
• Executive compensation through equity grants is a standard practice that can help retain key talent.

Future Outlook

The filing details a future grant and vesting schedule for executive stock options, indicating a long-term incentive structure for the Chief Legal Officer.

Industry Context

The grant of stock options to a Chief Legal Officer is a common practice in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate key executives by linking their compensation to the company's stock performance. This aligns with typical executive compensation strategies across publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across various industries, including biotech, aiming to align executive incentives with shareholder value.
• The vesting schedule, with a one-year cliff followed by monthly installments over three years, is a common structure designed to encourage long-term commitment and performance, comparable to practices at companies like Amgen or Gilead Sciences for similar roles, though specific grant sizes and exercise prices vary based on company size, performance, and individual role.

Related Party Transactions

• The grant of stock options to Erik Atkisson, Chief Legal Officer, constitutes a related party transaction as it involves compensation between the company and an executive.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Legal Officer's financial incentives with the company's stock performance, potentially benefiting shareholders through improved long-term value creation.
• Employees (Executive): Erik Atkisson receives a significant equity incentive, which can enhance retention and motivation.

Next Steps

• The stock options will begin vesting on the first anniversary of October 20, 2025, and continue monthly over 36 months, subject to continued service.

Key Dates

Keywords

ACHIEVE LIFE SCIENCES, ACHV, Stock Options, Executive Compensation, Form 4, Insider Transaction, Erik Atkisson, Chief Legal Officer